Hims & Hers Health (NYSE:HIMS) CFO Sells $187,938.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 7,950 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $23.64, for a total transaction of $187,938.00. Following the transaction, the chief financial officer directly owned 262,954 shares in the company, valued at $6,216,232.56. The trade was a 2.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.83, for a total transaction of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total transaction of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total value of $219,088.09.

Hims & Hers Health Stock Up 0.8%

HIMS traded up $0.18 during trading on Tuesday, reaching $22.47. 27,295,336 shares of the stock traded hands, compared to its average volume of 28,940,582. The stock’s 50-day simple moving average is $24.05 and its two-hundred day simple moving average is $28.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The stock has a market cap of $5.12 billion, a price-to-earnings ratio of -249.61, a price-to-earnings-growth ratio of 39.32 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. During the same period in the previous year, the company earned $0.20 earnings per share. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently bought and sold shares of the business. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter valued at about $28,000. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health during the fourth quarter worth about $28,000. Binnacle Investments Inc acquired a new stake in Hims & Hers Health during the third quarter valued at approximately $28,000. Bogart Wealth LLC grew its stake in shares of Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $30,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The larger financing gives Hims & Hers more capital to pursue international expansion, acquisition plans, and technology investment without using as much operating cash. Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
• Neutral Sentiment: Bank of America lowered its price target on Hims & Hers to $28 from $30 and kept a neutral rating, signaling more cautious expectations even though the target still sits above the recent share price. Benzinga report on Bank of America price target cut
• Negative Sentiment: Investors are worried the convertible notes could dilute shareholders later, which has contributed to the stock sliding after the financing announcement. Why Hims & Hers Stock Is Falling Today
• Negative Sentiment: The company’s latest earnings call and recent Q1 results have also kept sentiment weak, with the market still focused on the prior quarter’s earnings miss and softer-than-expected revenue. Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Jefferies Financial Group set a $24.50 price target on shares of Hims & Hers Health in a report on Tuesday, May 12th. Citigroup lifted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. UBS Group set a $35.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 12th. Finally, Evercore set a $24.00 target price on Hims & Hers Health in a report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $29.37.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.